Processes for Preparing 1,2-Substituted Cyclopropyl Derivatives
AssigneeAbbott Laboratories
InventorsYi-Yin Ku, Timothy A. Grieme, Jeffrey M. Kallemeyn, Mathew M. Mulhern
Life of this patent
Estimating the term…
Abstract
The present invention relates to processes for preparing enantiomerically pure cyclopropyl amine derivatives and salts thereof; the chiral intermediates such as the chiral salts are useful for the preparation of such chiral compounds and salts; pharmaceutical compositions comprising the compounds and salts; and method of using such compositions. The chiral cyclopropyl amine derivatives are useful for binding to histamine H3 receptor sites and for providing therapeutic agents for histamine H3 mediated disease.
Claims26
A process for preparing a chiral compound of formula:
- wherein R2, R3, R3a, R3b, are hydrogen;
- R1 is a 5- to 6-membered heteroaryl ring, cyanophenyl, a 8- to 12-membered bicyclic heteroaryl ring, or a 4- to 12-membered heterocyclic ring;
- and R4 and R5 taken together with the nitrogen atom to which they are attached form an amine moiety represented by structure:
- wherein R7, R8, R9, and R10 at each occurrence are independently selected from the group consisting of hydrogen, hydroxyalkyl, fluoroalkyl, cycloalkyl, and alkyl;
- R11, R12, R13, and R14 are each independently selected from the group consisting of hydrogen, hydroxyalkyl, alkyl, and fluoroalkyl;
- Rx and Ry are each independently selected from the group consisting of hydrogen, hydroxy, alkyl, alkoxy, alkylamino, fluoro, and dialkylamino;
- Q is O or S;
- and m is an integer from 1 to 5;
- comprising the steps of:
- a) providing enantiomerically pure chiral salts using chiral resolution with a chiral amine:
- wherein the chiral amine is selected from R-(−)-1-cyclohexylethylamine, (R)-(+)-α-methylbenzylamine, (S)-(−)-α-methylbenzylamine, (R)-(+)-N-benzyl-α-methylbenzylamine, (S)-(−)-N-benzyl-α-methylbenzylamine, (R)-(+)-N,N-dimethyl-1-phenylethylamine, (S)-(−)-N,N-dimethyl-1-phenylethylamine, [R-(R*,R*)]-(+)-bis(α-methylbenzyl)amine, [S-(R*,R*)]-(−)-bis(α-methylbenzyl)amine, (S)-(+)-1-cyclohexylethylamine, (R)-(+)-1-(1-naphthyl)ethylamine, (S)-(−)-1-(1-naphthyl)ethylamine, (1R,2R,3R,5S)-(−)-isopinocamphenylamine, (1S,2S,3S,5R)-(+)-isopinocamphenylamine, (1R2R)-(−)-pseudoephedrine, (1S,2S)-(+)-pseudoephedrine, (1R,2S)-(−)-ephedrine, (1S,2R)-(+)-ephedrine, (1R,2S)-(−)-N-methylephedrine, (1S,2R)-(+)-N-methylephedrine, (1R,2S)-(−)-norephedrine, (1S,2R)-(+)-norephedrine, (1R,2S)-(+)-cis-1-amino-2-indanol, (1S,2R)-(−)- cis-1-amino-2-indanol, quinine, and cinchonine;
- b) reacting the chiral pure arylcyclopropanecarboxylic acid after released from the chiral salt obtained from chiral resolution with an amine of formula:
- wherein R7, R8, R9, and R10 at each occurrence are independently selected from the group consisting of hydrogen, hydroxyalkyl, fluoroalkyl, cycloalkyl, and alkyl;
- R11, R12, R13, and R14 are each independently selected from the group consisting of hydrogen, hydroxyalkyl, alkyl, and fluoroalkyl;
- Rx and Ry are each independently selected from the group consisting of hydrogen, hydroxy, alkyl, alkoxy, alkylamino, fluoro, and dialkylamino;
- Q is O or S;
- and m is an integer from 1 to 5;
- and N,N′-carbonyldiimidazole in tetrahydrofuran to provide a chiral compound of structure:
- wherein X is chloro, bromo, iodo, or trifluoromethanesulfonate, and the amine moiety in the structure above is represented by:
- wherein R7, R8, R9, and R10 at each occurrence are independently selected from the group consisting of hydrogen, hydroxyalkyl, fluoroalkyl, cycloalkyl, and alkyl;
- R11, R12, R13, and R14 are each independently selected from the group consisting of hydrogen, hydroxyalkyl, alkyl, and fluoroalkyl;
- Rx and Ry are each independently selected from the group consisting of hydrogen, hydroxy, alkyl, alkoxy, alkylamino, fluoro, and dialkylamino;
- Q is O or S;
- and m is an integer from 1 to 5;
- c) reducing the product of step b to provide a compound of structure:
- wherein X and the amine moiety are as described above for compounds of step b);
- and
- d) treating the product of step c with a reagent selected from the group consisting of 5- to 6-membered heteroaryl, 8- to 12-membered bicyclic heteroaryl, and 4- to 12-membered heterocycloalkyl, and N,N′-dimethylethylenediamine, a copper catalyst, and base, in a basic solvent;
- to provide a compound of formula (II).
A process for preparing:
- comprising the step of reacting:
- with a chiral amine that is R-(−)-1-cyclohexylethylamine, (S)-(−)-α-methylbenzylamine, (R)-(+)-N-benzyl-α-methylbenzylamine, (S)-(−)—N-benzyl-α-methylbenzylamine, (R)-(+)-N,N-dimethyl-1-phenylethylamine, (S)-(−)-N,N-dimethyl-1-phenylethylamine, [R-(R*,R*)]-(+)-bis(α-methylbenzyl)amine, [S-(R*,R*)]-(−)-bis(α-methylbenzyl)amine, (S)-(+)-1-cyclohexylethylamine, (R)-(+)-1-(1-naphthyl)ethylamine, (S)-(−)-1-(1-naphthyl)ethylamine, (1R,2R,3R,5S)-(−)-isopinocamphenylamine, (1S,2S,3S,5R)-(+)-isopinocamphenylamine, (1R2R)-(−)-pseudoephedrine, (1S,2S)-(+)-pseudoephedrine, (1R,2S)-(−)-ephedrine, (1S,2R)-(+)-ephedrine, (1R,2S)-(−)-N-methylephedrine, (1S,2R)-(+)-N-methylephedrine, (1R,2S)-(−)-norephedrine, (1S,2R)-(+)-norephedrine, (1R,2S)-(+)-cis-1-amino-2-indanol, (1S,2R)-(−)- cis-1-amino-2-indanol, quinine, or cinchonine.
A compound that is:
- chiral 2-(4-bromophenyl)cyclopropanecarboxylic acid R-(−)-1-cyclohexylethylamine salt.
A compound that is:
- chiral 2-(4-bromophenyl)cyclopropanecarboxylic acid (R)-(+)-a-methylbenzylamine salt.
A compound of formula:
- wherein the amine moiety in the structure above is represented by:
- wherein R7, R8, R9, and R10 at each occurrence are independently selected from the group consisting of hydrogen, hydroxyalkyl, fluoroalkyl, cycloalkyl, and alkyl;
- R11, R12, R13, and R14 are each independently selected from the group consisting of hydrogen, hydroxyalkyl, alkyl, and fluoroalkyl;
- Rx and Ry are each independently selected from the group consisting of hydrogen, hydroxy, alkyl, alkoxy, alkylamino, fluoro, and dialkylamino;
- Q is O or S;
- and m is an integer from 1 to 5.
A compound of formula:
- wherein the amine moiety in the structure above is represented by:
- wherein R7, R8, R9, and R10 at each occurrence are independently selected from the group consisting of hydrogen, hydroxyalkyl, fluoroalkyl, cycloalkyl, and alkyl;
- R11, R12, R13, and R14 are each independently selected from the group consisting of hydrogen, hydroxyalkyl, alkyl, and fluoroalkyl;
- Rx and Ry are each independently selected from the group consisting of hydrogen, hydroxy, alkyl, alkoxy, alkylamino, fluoro, and dialkylamino;
- Q is O or S;
- and m is an integer from 1 to 5.
Dependencies are inferred from the claim text.